Literature DB >> 1387302

Comparison of the intracellular activities of clarithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals.

D M Yajko1, P S Nassos, C A Sanders, P C Gonzalez, W K Hadley.   

Abstract

The intracellular activities of clarithromycin and erythromycin, alone and in combination with other antimicrobial agents, were tested against Mycobacterium avium complex (MAC) strains inside mouse J774 cells and inside alveolar macrophages obtained from human immunodeficiency type 1-infected individuals. Clarithromycin alone had greater intracellular activity than erythromycin alone, and drug combinations that included clarithromycin were usually more active than combinations that included erythromycin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1387302      PMCID: PMC188858          DOI: 10.1128/AAC.36.5.1163

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex.

Authors:  S Naik; R Ruck
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Killing by antimycobacterial agents of AIDS-derived strains of Mycobacterium avium complex inside cells of the mouse macrophage cell line J774.

Authors:  D M Yajko; P S Nassos; C A Sanders; W K Hadley
Journal:  Am Rev Respir Dis       Date:  1989-11

3.  In-vitro activity of erythromycin against atypical mycobacteria.

Authors:  A Molavi; L Weinstein
Journal:  J Infect Dis       Date:  1971-02       Impact factor: 5.226

4.  Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages.

Authors:  C Perronne; A Gikas; C Truffot-Pernot; J Grosset; J J Pocidalo; J L Vilde
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

5.  In vitro and in vivo activities of clarithromycin against Mycobacterium avium.

Authors:  P B Fernandes; D J Hardy; D McDaniel; C W Hanson; R N Swanson
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

6.  [Bacteriostatic and bactericidal study of rifabutine and clofazimine in combination against Mycobacterium avium-intracellulare and Mycobacterium xenopi].

Authors:  M J Gevaudan; M N Mallet; C Bollet; C Gulian; P de Micco
Journal:  Pathol Biol (Paris)       Date:  1989-06

7.  Effects of antimicrobial agents on survival of Mycobacterium avium complex inside alveolar macrophages obtained from patients with human immunodeficiency virus infection.

Authors:  D M Yajko; P S Nassos; C A Sanders; W K Hadley
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

8.  Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages.

Authors:  C Perronne; A Gikas; C Truffot-Pernot; J Grosset; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

9.  Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome.

Authors:  D M Yajko; P S Nassos; W K Hadley
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

Review 10.  Antimicrobial drugs, microorganisms, and phagocytes.

Authors:  P J van den Broek
Journal:  Rev Infect Dis       Date:  1989 Mar-Apr
View more
  12 in total

Review 1.  Susceptibility testing of Mycobacterium avium complex isolates.

Authors:  L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

2.  The phagosomal environment protects virulent Mycobacterium avium from killing and destruction by clarithromycin.

Authors:  C Fréhel; C Offredo; C de Chastellier
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

3.  MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages.

Authors:  N Mor; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

4.  Inhibition of intracellular growth of Mycobacterium avium by one pulsed exposure of infected macrophages to clarithromycin.

Authors:  N Mor; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

5.  Mycobacterium avium strains resistant to clarithromycin and azithromycin.

Authors:  L Heifets; N Mor; J Vanderkolk
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

6.  In vitro activities of rifabutin, azithromycin, ciprofloxacin, clarithromycin, clofazimine, ethambutol, and amikacin in combinations of two, three, and four drugs against Mycobacterium avium.

Authors:  D M Yajko; C A Sanders; J J Madej; V L Cawthon; W K Hadley
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 7.  Mycobacterium avium complex: advances in therapy.

Authors:  D V Havlir
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

Review 8.  Clarithromycin. A review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with acquired immune deficiency syndrome.

Authors:  L B Barradell; G L Plosker; D McTavish
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

Review 9.  Animal and cell-culture models for the study of mycobacterial infections and treatment.

Authors:  I M Orme; A D Roberts; S K Furney; P S Skinner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

Review 10.  The Mycobacterium avium complex.

Authors:  C B Inderlied; C A Kemper; L E Bermudez
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.